Eupraxia Pharmaceuticals (NASDAQ:EPRX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced its quarterly earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.03, Zacks reports.

Here are the key takeaways from Eupraxia Pharmaceuticals’ conference call:

• Eupraxia says its Diffusphere platform can deliver fluticasone locally with one endoscopic injection, targeting roughly a year of treatment. In open-label EoE studies, the company reports clinical remission in 80% of patients at six months and 64% at 52 weeks; these results have not yet been confirmed against placebo.
• A Phase IIb interim readout is expected to include six-month placebo comparisons across symptoms, histology, endoscopic findings and safety, plus 52-week durability data. The interim analysis is not powered for statistical significance, so the company will look for evidence of separation from placebo; the completed trial is larger, with 40 patients per arm.
• Management described a substantial and growing U.S. EoE population, citing estimates of 500,000–600,000 patients, and highlighted challenges with daily oral therapies, including administration demands and candidiasis. The company argues that a treatment given during an already recommended annual endoscopy could improve adherence.
• The CEO said the company has seen no injection-related complications across about 3,000 injections and no candidiasis to date, though larger controlled trials will be needed to establish the safety profile. Management also pointed to possible expansion into benign esophageal strictures and, later, Crohn’s disease, while targeting an EoE Phase III start in mid-2027.
• Management believes the procedure could fit gastroenterologists’ existing practices and be reimbursed through the medical benefit, potentially supporting physician adoption. These commercial and reimbursement assumptions have yet to be validated in the market.

Eupraxia Pharmaceuticals Price Performance

EPRX opened at $7.63 on Wednesday. Eupraxia Pharmaceuticals has a fifty-two week low of $5.63 and a fifty-two week high of $9.32. The firm has a 50-day moving average of $7.58 and a 200 day moving average of $7.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00. The firm has a market cap of $513.04 million, a P/E ratio of -7.48 and a beta of 1.04.

Analyst Ratings Changes

Several equities analysts have commented on EPRX shares. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday. Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 8th. Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $17.17.

Key Stories Impacting Eupraxia Pharmaceuticals

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: Eupraxia reported a third-quarter 2026 loss of $0.23 per share, narrower than the $0.26 loss analysts expected. The earnings beat may be encouraging, although the company remains loss-making. Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: RBC Capital initiated coverage with an Outperform rating and a $14 price target, while flagging the stock as speculative risk. The rating signals analyst optimism, balanced by the high-risk designation. RBC Capital Starts Eupraxia Pharmaceuticals at Outperform
• Negative Sentiment: The company established a $125 million at-the-market offering program, allowing it to sell shares over time. The financing provides access to capital but could dilute existing shareholders if shares are issued. Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.